Collaboration, acquisition and license agreements are written with an optimistic view of the chances for commercial success. Nevertheless, they can neglect to clarify the parties’ expectations in the event of program failure, delay or disagreement—all common occurrences in biopharma development and commercialization.
This panel looks to the experience of deal-makers, alliance managers and sell-and buy-side dispute managers on how both to anticipate and to avoid costly disputes at three critical stages: 1) during deal formation and the exchange of terms; 2) during post-closing operations and integration; and 3) in formal disputes. The panelists’ advice and lessons will assist licensors/licensees, sellers/buyers and collaborators of single and multi-asset programs and platform technologies.
Ability Level: Intermediate
Session ID: 19809